EPAS1 and neoplasm: There are not yet any functional Notch inhibitors in clinical use [54], but if key tumor-promoting features of hyperactivated Notch signaling would stem from a HIF2α-dependent portion of the Notch transcriptome, blocking HIF2α would represent an interesting alternative approach to curtail the adverse effects of dysregulated Notch signaling.